• Explore /
  • Poster
  • / Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance.

Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance.

Abstract Poster

Authors

Kellogg Parsons

J Kellogg Parsons

Janssen Research and Development, LLC, San Diego, CA

J Kellogg Parsons , Peter A. Pinto , Howard L. Parnes , Christian P. Pavlovich , Edward M. Uchio , Mike Minh Nguyen , Hyung Lae Kim , James L. Gulley , Houssein Abdul Sater , Christina Jamieson , Chiu-Hsieh Hsu , Malgorzata E. Wojtowicz , Jeffrey Schlom , Renee Nicole Donahue , Sara Centuori , Shania Bailey , Julie E. Bauman , H H Chow

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02326805

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 249)

DOI

10.1200/JCO.2022.40.6_suppl.249

Abstract #

249

Poster Bd #

L3

Abstract Disclosures

Similar Posters

Poster

2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Results of a phase Ib trial of encapsulated rapamycin in prostate cancer patients under active surveillance to prevent progression.

Results of a phase Ib trial of encapsulated rapamycin in prostate cancer patients under active surveillance to prevent progression.

First Author: Phillip M. Kemp Bohan

First Author: Mark N. Stein

First Author: David D. Chism

First Author: Bridget F. Koontz